Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184890/abstract
Dive into the SYNC-T technology by Syncromune® Inc. and its groundbreaking approach to hormone-refractory prostate cancer. Learn how it stimulates an immune response within the…
Introduction to Emerging Therapies in ALL Management … Dr. Elias Jabbour shared recent developments in the treatment of acute lymphoblastic leukemia (ALL) during a recent…
Dr. Scott Kopetz discussed the KRYSTAL-1 study at AACR, presenting promising results of combining adagrasib and cetuximab to target KRASG12C mutated colorectal cancer, reporting a…
Dr. Ajay Goel presented a novel blood-based liquid biopsy for early detection of pancreatic cancer, utilizing a combination of microRNAs and exosomes to achieve a…
Dr. Ajay Goel presented a novel blood-based liquid biopsy for early detection of pancreatic cancer, utilizing a combination of microRNAs and exosomes to achieve a…
Uncover a revolutionary approach to pancreatic cancer detection. Delve into the study’s methodology and learn how microRNAs are used in liquid biopsies for unparalleled accuracy.
Uncover the impact of SCD1 in NSCLC with concurrent KRAS, STK11, and KEAP1 mutations. Learn about the potential of SCD1 as a novel therapeutic target…
Learn about the remarkable response rate and complete response rate of Lenvosiltamab in multiple myeloma patients. Explore this potential paradigm shift in treatment.
Find out how combining traditional chemotherapies with Lurbinectedin can improve outcomes in small cell lung cancer. Discover the therapeutic potential of this innovative treatment.
Mojtaba Akhtari, MD, FACP-Professor of Medicine-Loma Linda University explains the Efficacy and Safety of Inotuzumab Ozogamicin – from the MOASC 2024 Advances in Oncology meeting…
